Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Pediatric Sarcoma, Refractory: early-phase trial registry

1 of 1 indexed Pediatric Sarcoma, Refractory trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Pediatric Sarcoma, Refractory: 1 US clinical trial tracked, 1 recruiting.

Pediatric Sarcoma, Refractory is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Nationwide Children's Hospital, running 1 of these trials.

Enrollment posture brief

Registry condition pediatric-sarcoma-refractory

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Pediatric Sarcoma, Refra (this)Pediatric Sarcoma, Refra (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Pediatric Sarcoma, Refractory

Pediatric Sarcoma, Refractory lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pediatric Sarcoma, Refractory on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pediatric Sarcoma, Refractory is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Pediatric Sarcoma, Refractory records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

GEM/DOX + TGFBi expanded NK cells Biological
1 trials

US sites by state

Facility locations filed on Pediatric Sarcoma, Refractory trials. A trial with sites in several states counts in each.

Texas 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Missouri 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pediatric Sarcoma, Refractory page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pediatric Sarcoma, Refractory condition card totals 1 registered trials; most-linked intervention GEM/DOX + TGFBi expanded NK cells; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.